169 related articles for article (PubMed ID: 38654814)
1. Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide.
Baagar KA; Sadiq A; Khan AA; Dabbous Z; Rohani Z
Qatar Med J; 2024; 2024(1):17. PubMed ID: 38654814
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
[TBL] [Abstract][Full Text] [Related]
4. De-escalation treatment with pasireotide for acromegaly: a long-term experience.
Giampietro A; Menotti S; Chiloiro S; Pontecorvi A; De Marinis L; Bianchi A
Endocrine; 2023 Jun; 80(3):505-510. PubMed ID: 36808072
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly.
Amarawardena WKMG; Liyanarachchi KD; Newell-Price JDC; Ross RJM; Iacovazzo D; Debono M
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28721221
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia.
Gordon MB; Spiller KL
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28567297
[TBL] [Abstract][Full Text] [Related]
8. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.
Daly AF; Rostomyan L; Betea D; Bonneville JF; Villa C; Pellegata NS; Waser B; Reubi JC; Waeber Stephan C; Christ E; Beckers A
Endocr Connect; 2019 Apr; 8(4):367-377. PubMed ID: 30851160
[TBL] [Abstract][Full Text] [Related]
9. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of long-acting pasireotide in acromegaly.
Akirov A; Gorshtein A; Dotan I; Khazen NS; Pauker Y; Gershinsky M; Shimon I
Endocrine; 2021 Nov; 74(2):396-403. PubMed ID: 34081309
[TBL] [Abstract][Full Text] [Related]
11. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
Vilar L; Azevedo MF; Naves LA; Casulari LA; Albuquerque JL; Montenegro RM; Montenegro RM; Figueiredo P; Nascimento GC; Faria MS
Pituitary; 2011 Jun; 14(2):148-56. PubMed ID: 21104199
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Khandji AG; Post KD
Pituitary; 2004; 7(1):21-30. PubMed ID: 15638294
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
[TBL] [Abstract][Full Text] [Related]
14. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
[TBL] [Abstract][Full Text] [Related]
15. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
Ilie MD; Raverot G; Brac de la Perrière A
Eur J Endocrinol; 2024 Jan; 190(1):K17-K20. PubMed ID: 38128124
[TBL] [Abstract][Full Text] [Related]
17. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide therapy in a rare and unusual case of plurihormonal pituitary macroadenoma.
Rajendran R; Naik S; Sandeman DD; Nasruddin AB
Endocrinol Diabetes Metab Case Rep; 2013; 2013():130026. PubMed ID: 24616766
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs.
Gadelha M; Bex M; Colao A; Pedroza García EM; Poiana C; Jimenez-Sanchez M; Yener S; Mukherjee R; Bartalotta A; Maamari R; Raverot G
Front Endocrinol (Lausanne); 2019; 10():931. PubMed ID: 32117045
[No Abstract] [Full Text] [Related]
20. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.
Stelmachowska-Banaś M; Czajka-Oraniec I; Tomasik A; Zgliczyński W
Pituitary; 2022 Feb; 25(1):180-190. PubMed ID: 34498217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
